Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Efbemalenograstim Alfa→

Efbemalenograstim Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2200269-79-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Long-acting granulocyte colony-stimulating factor (G-CSF) analogpegylated leukocyte growth factor
Mechanism of action
Binds G-CSF receptors on haematopoietic progenitor cells and neutrophils, stimulating proliferation, differentiation and survival of neutrophil precursors and increasing circulating neutrophil counts.
Indications / reported uses
  • To decrease the incidence of infection, manifested as febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia; not indicated for peripheral-blood stem-cell mobilisation

Sources: NLM DailyMed — RYZNEUTA (efbemalenograstim alfa-vuxw), label updated 19 May 2026 · FDA label — RYZNEUTA · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Long-acting granulocyte colony-stimulating factor (G-CSF) analog; pegylated leukocyte growth factor

Mechanism of action

Binds G-CSF receptors on haematopoietic progenitor cells and neutrophils, stimulating proliferation, differentiation and survival of neutrophil precursors and increasing circulating neutrophil counts.

General use cases

  • To decrease the incidence of infection, manifested as febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia; not indicated for peripheral-blood stem-cell mobilisation

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Efbemalenograstim Alfa Environmental Risk Assessment (ERA) (the Efbemalenograstim Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.